Arcturus Therapeutics Holdings Inc.
ARCT
NASDAQ·Healthcare·Biotechnology·Mkt cap $449.7M
$15.82
▲ +1.67%
P/E
-4.75
Mkt Cap
$449.7M
52-Wk Range
$5.50–$24.17
52-Week Range
$5.50 - $24.17
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 11.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary self-amplifying RNA (saRNA) and mRNA technology platforms
- Strategic partnerships with major pharmaceutical companies (Janssen, CureVac, Ultragenyx)
- Diversified pipeline addressing rare genetic diseases and infectious disease vaccines
- Experienced management team with deep RNA therapeutics expertise
Bear Case
1 risk
- High volatility (beta 2.5). Larger-than-normal price swings expected.
Growth
Revenue decline expected
Clinical advancement of LUNAR-OTC and LUNAR-CF programs for rare diseases
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+122.2% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ARCT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 6, 2026
Reported EPS of -$0.84 vs -$1.00 consensus (+15.7% surprise). Revenue of $3.0M vs $3.1M expected (-4.8%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+15.7%
Revenue trend · last 8Q
—
-16%
-10%
-47%
-56%
-85%
-98%
-82%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$38.8M
$21.0M
$29.4M
$24.5M
$17.2M
$3.1M
$610.0K
$4.4M
Margins · last 8Q
Gross
1.1%
Operating
—
Profit
696.5%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Roth Capital · Sep 2, 2026
vs Industry
How ARCT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related